PharmaBlock Sciences Nanjing Inc
SZSE:300725
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PharmaBlock Sciences Nanjing Inc
Common Stock
PharmaBlock Sciences Nanjing Inc
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PharmaBlock Sciences Nanjing Inc
SZSE:300725
|
Common Stock
¥233.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Common Stock
¥53k
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Common Stock
¥6.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Common Stock
¥1.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Common Stock
¥3.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Common Stock
¥401m
|
CAGR 3-Years
4%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
PharmaBlock Sciences Nanjing Inc
Glance View
PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.
See Also
What is PharmaBlock Sciences Nanjing Inc's Common Stock?
Common Stock
233.8m
CNY
Based on the financial report for Sep 30, 2025, PharmaBlock Sciences Nanjing Inc's Common Stock amounts to 233.8m CNY.
What is PharmaBlock Sciences Nanjing Inc's Common Stock growth rate?
Common Stock CAGR 5Y
10%
Over the last year, the Common Stock growth was 17%. The average annual Common Stock growth rates for PharmaBlock Sciences Nanjing Inc have been 5% over the past three years , 10% over the past five years .
